炔雌醇20 μg/屈螺酮3 mg柔性扩展方案治疗子宫内膜异位症相关盆腔痛:一项随机对照试验
这项3期随机、双盲、安慰剂对照、平行组研究在32个中心纳入312例子宫内膜异位症患者,比较炔雌醇20 μg/屈螺酮3 mg柔性扩展方案(FlexibleMIB)、安慰剂与地诺孕素。FlexibleMIB较安慰剂显著降低最严重子宫内膜异位症相关盆腔痛(视觉模拟评分平均差-26.3 mm),并改善其他疼痛与妇科所见、缩小子宫内膜异位囊肿,耐受性良好。
要点
- FlexibleMIB较安慰剂显著降低最严重子宫内膜异位症相关盆腔痛,视觉模拟评分平均差为-26.3 mm。
- FlexibleMIB还改善其他子宫内膜异位症相关疼痛与妇科所见,并缩小子宫内膜异位囊肿。
- FlexibleMIB耐受性良好,作者认为其可能成为管理子宫内膜异位症的新选择。
核心结论
- FlexibleMIB改善子宫内膜异位症相关盆腔痛且耐受性良好,提示其可能成为管理子宫内膜异位症的新替代选择。
研究设计与样本
- 3期随机、双盲、安慰剂对照、平行组研究,含24周双盲治疗期及随后28周开放标签扩展期(设非盲对照臂),共32个中心、312例子宫内膜异位症患者。
- 患者随机分入FlexibleMIB组、安慰剂组或地诺孕素组;FlexibleMIB组与安慰剂组每日连续服1片共120天,在120天后或第25-120天连续≥3天点滴出血和/或出血后设4天停药间期。
- 24周后安慰剂组改为FlexibleMIB;随机分入地诺孕素组者在非盲对照臂接受2 mg/d共52周。
主要发现
- 与安慰剂相比,FlexibleMIB显著降低最严重子宫内膜异位症相关盆腔痛,视觉模拟评分平均差为-26.3 mm。
- FlexibleMIB还改善其他子宫内膜异位症相关疼痛与妇科所见,并缩小子宫内膜异位囊肿。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen (FlexibleMIB) compared with placebo to treat endometriosis-associated pelvic pain (EAPP). DESIGN: A phase 3, randomized, double-blind, placebo-controlled, parallel-group study, consisting of a 24-week double-blind treatment phase followed by a 28-week open-label extension phase with an unblinded reference arm. SETTING: Thirty-two centers. PATIENT(S): A total of 312 patients with endometriosis. INTERVENTION(S): Patients were randomized to FlexibleMIB, placebo, or dienogest. The FlexibleMIB and placebo arms received 1 tablet per day continuously for 120 days, with a 4-day tablet-free interval either after 120 days or after ≥3 consecutive days of spotting and/or bleeding on days 25-120. After 24 weeks, placebo recipients were changed to FlexibleMIB. Patients randomized to dienogest received 2 mg/d for 52 weeks in an unblinded reference arm. MAIN OUTCOME MEASURE(S): Absolute change in the most severe EAPP based on visual analog scale scores from the baseline observation phase to the end of the double-blind treatment phase. RESULT(S): Compared with placebo, FlexibleMIB significantly reduced the most severe EAPP (mean difference in visual analog scale score: -26.3 mm). FlexibleMIB also improved other endometriosis-associated pain and gynecologic findings and reduced the size of endometriomas. CONCLUSION(S): FlexibleMIB improved EAPP and was well tolerated, suggesting it may be a new alternative for managing endometriosis. CLINICAL TRIALS REGISTRATION NUMBER: NCT01697111.
引用
- Harada T, Kosaka S, Elliesen J, et al. Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. Fertil Steril. 2017. PMID: 28911925. doi:10.1016/j.fertnstert.2017.07.1165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。